Diagnosis and treatment of myocardial infarction in patient with end - stage renal disease on chronic hemodialysis
- Authors: Antukh D.E1, Shchekochikhin D.Y.1, Nesterov A.P2, Gilarov M.Y.2
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Pirogov Russian National Research Medical University
- Issue: Vol 91, No 6 (2019)
- Pages: 137-144
- Section: Articles
- URL: https://journals.rcsi.science/0040-3660/article/view/59014
- DOI: https://doi.org/10.26442/00403660.2019.06.000203
- ID: 59014
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
D. E Antukh
Sechenov First Moscow State Medical University (Sechenov University)
Email: dimst@list.ru
студент ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Moscow, Russia
D. Yu Shchekochikhin
Sechenov First Moscow State Medical University (Sechenov University)доц. каф. профилактической и неотложной кардиологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Moscow, Russia
A. P Nesterov
Pirogov Russian National Research Medical Universityдоц. каф. интервенционной кардиологии и кардиореабилитации ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Moscow, Russia
M. Yu Gilarov
Pirogov Russian National Research Medical Universityзав. каф. интервенционной кардиологии и кардиореабилитации ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Moscow, Russia
References
- Gilbertson D, Ishani A, Kasiske B.L, Liu J. Excerpts From the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis. 2011;55(Suppl 1):2010-1. doi: 10.1053/j.ajkd.2009.10.009
- Herzog C.A. How to manage the renal patient with coronary heart disease: The agony and the ecstasy of opinion - based medicine. J Am Soc Nephrol. 2003;14(10):2556-72. doi: 10.2308/ajpt-50738
- Cheung A.K, Sarnak M.J, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int. 2004;65(6):2380-9. doi: 10.1111/j.1523-1755.2004.00657.x
- Respalacios F.E.C.T, Aylor A.L.J.T, Godoa L.A.Y.A, et al. Incident acute coronary syndromes in chronic dialysis patients in the United States 1. Kidney Int. 2002;62:1799-805. doi: 10.1046/j.1523-1755.2002.00638.x
- Parekh R.S, Zhang L, Fivush B.A, Klag M.J. Incidence of Atherosclerosis by Race in the Dialysis Morbidity and Mortality Study: A Sample of the US ESRD Population. J Am Soc Nephrol. 2005:1420-6. doi: 10.1681/ASN.2004080661
- Young B.A, Rudser K, Kestenbaum B, Seliger S.L, Andress D, Boyko E.J. Racial and ethnic differences in incident myocardial infarction in end - stage renal disease patients: The USRDS. Kidney Int. 2006;69(9):1691-8. doi: 10.1038/sj.ki.5000346
- Conlon P.J, Krucoff M.W, Minda S, Schumm D, Schwab S.J. Incidence and long - term significance of transient ST segment deviation in hemodialysis patients. Clin Nephrol. 1998;49(4):236-9.
- Go A.S, Bansal N.M.C. Chronic Kidney Disease and Risk of Presenting with Acute Myocardial Infarction versus Stable Exertional Angina in Adults with Coronary Heart Disease. NeuroImage. 2011;85(01):1-27. doi: 10.1016/j.neuroimage.2013.08.045
- Herzog C.A, Littrell K, Arko C, Frederick P.D, Blaney M. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: A collaborative project of the United States renal data system and the national registry of myocardial infarction. Circulation. 2007;116(13):1465-72. doi: 10.1161/CIRCULATIONAHA.107.696765
- Shroff G.R, Frederick P.D, Herzog C.A. Renal failure and acute myocardial infarction: Clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J. 2012;163(3):399-406. doi: 10.1016/j.ahj.2011.12.002
- Fox C.S, Muntner P, Chen A.Y, et al. Use of evidence - based therapies in short - term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: A report from the national cardiovascular data acute coronary. Circulation. 2010;121(3):357-65. doi: 10.1161/CIRCULATIONAHA.109.865352
- Szummer K, Lundman P, Jacobson S.H, et al. Relation between renal function, presentation, use of therapies and in - hospital complications in acute coronary syndrome: Data from the SWEDEHEART register. J Intern Med. 2010;268(1):40-9. doi: 10.1111/j.1365-2796.2009.02204.x
- Surana S.P, Riella L.V, Keithi-Reddy S.R, Charytan D.M, Singh A.K. Acute coronary syndrome in ESRD patients. Kidney Int. 2009;75(5):558-62. doi: 10.1038/ki.2008.233
- Thygesen K, Alpert J.S, Jaffe A.S, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;1. doi: 10.1016/j.gheart.2018.08.004
- Dubin R.F, Li Y, He J, et al. Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: A cross - sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol. 2013;14(1). doi: 10.1186/1471-2369-14-229
- Van der Linden N, Cornelis T, Kimenai D.M, et al. Origin of Cardiac Troponin T Elevations in Chronic Kidney Disease. Circulation. 2017;136(11):1073-5. doi: 10.1161/CIRCULATIONAHA.117.029986
- Stacy S.R, Suarez-Cuervo C, Berger Z, et al. Role of troponin in patients with chronic kidney disease and suspected acute coronary syndrome: A systematic review. Ann Intern Med. 2014;161(7):502-12. doi: 10.7326/M14-0746
- Twerenbold R, Wildi K, Jaeger C, et al. Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. Circulation. 2015;131(23):2041-50. doi: 10.1161/CIRCULATIONAHA.114.014245
- Roffi M, Patrono C, Collet J.P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent st - segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of. Eur Heart J. 2016;37(3):267-315. doi: 10.1093/eurheartj/ehv320
- Miller-Hodges E, Anand A, Shah A.S.V, et al. High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients with Renal Impairment Presenting with Suspected Acute Coronary Syndrome. Circulation. 2018;137(5):425-35. doi: 10.1161/CIRCULATIONAHA.117.030320
- Twerenbold R, Badertscher P, Boeddinghaus J, et al. 0/1-Hour Triage Algorithm for Myocardial Infarction in Patients with Renal Dysfunction. Circulation. 2018;137(5):436-51. doi: 10.1161/CIRCULATIONAHA.117.028901
- Martin G.S, Becker B.N, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. Nephrol Dial Transplant. 1998;13(7):1709-12. http://www.ncbi.nlm.nih.gov/pubmed/9681716
- Newby L.K, Jesse R.L, Babb J.D, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2012;60(23):2427-63. doi: 10.1016/j.jacc.2012.08.969
- Apple F.S, Murakami M.M, Pearce L.A, Herzog C.A. Predictive value of cardiac troponin I and T for subsequent death in end - stage renal disease. Circulation. 2002;106(23):2941-45. http://www.ncbi.nlm.nih.gov/pubmed/12460876
- Morrow D.A, Bonaca M.P. Real - world application of “delta” troponin: Diagnostic and prognostic implications. J Am Coll Cardiol. 2013;62(14):1239-41. doi: 10.1016/j.jacc.2013.06.049
- Bjurman C, Larsson M, Johanson P, et al. Small changes in troponin T levels are common in patients with non-ST-segment elevation myocardial infarction and are linked to higher mortality. J Am Coll Cardiol. 2013;62(14):1231-8. doi: 10.1016/j.jacc.2013.06.050
- Tun A, Khan I.A, Win M.T, et al. Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long - term hemodialysis patients and effect of hemodialysis on these cardiac markers. Cardiology. 1998;90(4):280-5. doi: 10.1159/000006859
- Lippi G, Tessitore N, Montagnana M, Salvagno G.L, Lupo A, Guidi G.C. Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. Arch Pathol Lab Med. 2008;132(1):72-6. doi: 10.1043/1543-2165(2008)132[72:IOSTAU]2.0.CO;2
- Wayand D, Baum H, Schatzle G, Scharf J, Neumeier D. Cardiac troponin T and I in end - stage renal failure. Clin Chem. 2000;46(9):1345-50.
- Nevis I.F, Mathew A, Novick R.J, et al. Optimal method of coronary revascularization in patients receiving dialysis: Systematic review. Clin J Am Soc Nephrol. 2009;4(2):369-78. doi: 10.2215/CJN.02640608
- Wang Y, Zhu S, Gao P, Zhang Q. Comparison of coronary artery bypass grafting and drug - eluting stents in patients with chronic kidney disease and multivessel disease: A meta - analysis. Eur J Intern Med. 2017;43(2016):28-35. doi: 10.1016/j.ejim.2017.04.002
- Möckel M, Searle J, Baberg H.T, et al. Revascularisation of patients with end - stage renal disease on chronic haemodialysis: bypass surgery versus PCI-analysis of routine statutory health insurance data. Open Hear. 2016;3(2):e000464. doi: 10.1136/openhrt-2016-000464
- Krishnaswami A, Mc Culloch C.E, Tawadrous M, et al. Coronary artery bypass grafting and percutaneous coronary intervention in patients with end - stage renal disease. Eur J Cardio - thoracic Surg. 2015;47(5):e193-e198. doi: 10.1093/ejcts/ezv104
- Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan E.L. Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. J Am Coll Cardiol. 2015;66(11):1209-20. doi: 10.1016/j.jacc.2015.06.1334
- Shroff G.R, Solid C.A, Herzog C.A. Long - term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug - eluting and bare metal stents in the united states. Circulation. 2013;127(18):1861-9. doi: 10.1161/CIRCULATIONAHA.112.001264
- Hemmelgarn B.R, Southern D, Culleton B.F, et al. Survival after coronary revascularization among patients with kidney disease. Circulation. 2004;110(14):1890-5. doi: 10.1161/01.CIR.0000143629.55725.D9
- Chen J-J, Lin L-Y, Yang Y-H, et al. On pump versus off pump coronary artery bypass grafting in patients with end - stage renal disease and coronary artery disease - A nation - wide, propensity score matched database analyses. Int J Cardiol. 2017;227:529-34. doi: 10.1016/j.ijcard.2016.10.108
- Aoyama T, Ishii H, Toriyama T, et al. Sirolimus - eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J. 2008;72(1):56-60.
- Yachi S, Tanabe K, Tanimoto S, et al. Clinical and Angiographic Outcomes Following Percutaneous Coronary Intervention With Sirolimus-Eluting Stents Versus Bare-Metal Stents in Hemodialysis Patients. Am J Kidney Dis. 2009;54(2):299-306. doi: 10.1053/j.ajkd.2009.01.263
- Chang T.I, Montez-Rath M.E, Tsai T.T, Hlatky M.A, Winkelmayer W.C. Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on Dialysis. J Am Coll Cardiol. 2016;67(12):1459-69. doi: 10.1016/j.jacc.2015.10.104
- Li S, Ye D, Chen G, Xu W. Meta-Analysis of Comparison of Drug-Eluting Stents and Bare-Metal Stents in Patients on Dialysis. Am J Cardiol. 2017;119(8):1186-92. doi: 10.1016/j.amjcard.2016.12.036
- Kaufman J.S, O’Connor T.Z, Zhang J.H, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003;14(9):2313-21.
- Hiremath S, Holden R.M, Fergusson D, Zimmerman D.L. Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin J Am Soc Nephrol. 2009;4(8):1347-55. doi: 10.2215/CJN.00810209
- Herzog C.A. The optimal method of coronary revascularization in dialysis patients: choosing between a rock and a hard place. Int J Artif Organs. 2000;23(4):215-8. http://www.ncbi.nlm.nih.gov/pubmed/ 10832653
- K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1-153.
- Sorrell V.L. Diagnostic tools and management strategies for coronary artery disease in patients with end - stage renal disease. Semin Nephrol. 2001;21(1):13-24.
- Frilling B, Zahn R, Fraiture B, et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol. 2002;89(4):450-2.
- Best P.J.M, Lennon R, Gersh B.J, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J. 2003;146(2):345-50. doi: 10.1016/S0002-8703(03)00231-X
- Jeremias A, Bhatt D.L, Chew D.P, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol. 2002;89(10):1209-11.
- Khaja A, Garg R, Govindarajan G, Madsen R, Aggarwal K. Percutaneous coronary intervention and the use of glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease on dialysis: A single center experience. Hemodial Int. 2008;12:S2-S8. doi: 10.1111/j.1542-4758.2008.00316.x
- Freeman R.V, Mehta R.H, Al Badr W, Cooper J.V, Kline-Rogers E, Eagle K.A. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol. 2003;41(5):718-24.
- Tsai T.T, Maddox T.M, Roe M.T, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA. 2009;302(22):2458-64. doi: 10.1001/jama.2009.1800
- Ifudu O, Miles A.M, Friedman E.A. Hemodialysis immediately after acute myocardial infarction. Nephron. 1996;74(1):104-9. doi: 10.1159/000189287
- Coritsidis G, Sutariya D, Stern A, et al. Does timing of dialysis in patients with ESRD and acute myocardial infarcts affect morbidity or mortality? Clin J Am Soc Nephrol. 2009;4(8):1324-30. doi: 10.2215/CJN.04470908
- Chapter 1: Definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19-62. doi: 10.1038/kisup.2012.64
- Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-48. doi: 10.1056/NEJMoa043545
- Fellström B.C, Jardine A.G, Schmieder R.E, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-407. doi: 10.1056/NEJMoa0810177
- Baigent C, Landray M.J, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo - controlled trial. Lancet (London, England). 2011;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3
- Upadhyay A, Earley A, Lamont J.L, Haynes S, Wanner C, Balk E.M. Lipid - lowering therapy in persons with chronic kidney disease: a systematic review and meta - analysis. Ann Intern Med. 2012;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005
- Palmer S.C, Craig J.C, Navaneethan S.D, Tonelli M, Pellegrini F, Strippoli G.F.M. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta - analysis. Ann Intern Med. 2012;157(4):263-75. doi: 10.7326/0003-4819-157-4-201208210-00007
- Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta - analysis. Eur Heart J. 2013;34(24):1807-17. doi: 10.1093/eurheartj/eht065
- Ethier J, Bragg-Gresham J.L, Piera L, et al. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2007;50(4):602-11. doi: 10.1053/j.ajkd.2007.07.007
- Chan K.E, Lazarus J.M, Thadhani R, Hakim R.M. Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients. J Am Soc Nephrol. 2009;20(4):872-81. doi: 10.1681/ASN.2008080824
- Palmer S.C, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Palmer S.C, ed. Cochrane Database Syst Rev. 2013;(2):CD008834. doi: 10.1002/14651858.CD008834.pub2
- Foundation: NK. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney. 2005;45(4):51-3. doi: 10.1053/j.ajkd.2005.01.016
- Berger A.K, Duval S, Krumholz H.M. Aspirin, beta - blocker, and angiotensin - converting enzyme inhibitor therapy in patients with end - stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201-8.
- Knoll G.A, Sahgal A, Nair R.C, Graham J, van Walraven C, Burns K.D. Renin - angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002;112(2):110-4.
- Miskulin D, Sarnak M. A β - blocker trial in dialysis patients: Is it feasible and worthwhile? Am J Kidney Dis. 2016;67(6):822-5. doi: 10.1053/j.ajkd.2016.03.413
- Weir M.A, Dixon S.N, Fleet J.L, et al. β - Blocker Dialyzability and Mortality in Older Patients Receiving Hemodialysis. J Am Soc Nephrol. 2015;26(4):987-96. doi: 10.1681/ASN.2014040324
- Struthers A, Mac Donald T.M. Review of aldosterone - and angiotensin II - induced target organ damage and prevention. Cardiovasc Res. 2004;61(4):663-70. doi: 10.1016/j.cardiores.2003.11.037
- Quach K, Lvtvyn L, Baigent C, et al. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta - analysis. Am J Kidney Dis. 2016;68(4):591-8. doi: 10.1053/j.ajkd.2016.04.011
- Zhao Y, Yan B, Zhao Z, Wang S, Weng X. Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: A systematic review and meta - analysis. Ren Fail. 2016;38(4):589-99. doi: 10.3109/0886022X.2016.1149684
- Flevari P, Kalogeropoulou S, Drakou A, et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens. 2013;31(6):1239-44. doi: 10.1097/HJH.0b013e32835f955c
- Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients. J Am Coll Cardiol. 2014;63(6):528-36. doi: 10.1016/j.jacc.2013.09.056
- Hammer F, Krane V, Störk S, et al. Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol Dial Transplant. 2014;29(2):400-5. doi: 10.1093/ndt/gft409
- Walsh M, Manns B, Garg A.X, et al. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial. Clin J Am Soc Nephrol. 2015;10(9):1602-8. doi: 10.2215/CJN.12371214
- Herzog C.A, Ma J.Z, Collins A.J. Poor long - term survival after acute myocardial infarction among patients on long - term dialysis. N Engl J Med. 1998;339(12):799-805. doi: 10.1056/NEJM199809173391203
- Chertow G.M, Normand S.L, Silva L.R, Mc Neil B.J. Survival after acute myocardial infarction in patients with end - stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis. 2000;35(6):1044-51.
- Iseki K, Fukiyama K. Long - term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis. 2000;36(4):820-5.
- Baber U, Kini A.S, Sharma S.K, Kim M.C, Farkouh M.E, Muntner P. Thrombolysis In Myocardial Infarction (TIMI) risk score and mortality in patients with advanced chronic kidney disease and on dialysis. Am J Cardiol. 2009;103(11):1513-7. doi: 10.1016/j.amjcard.2009.01.364
- Michos E.D, Wilson L.M, Yeh H-C, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta - analysis. Ann Intern Med. 2014;161(7):491-501. doi: 10.7326/M14-0743
- Hickson L.J, Cosio F.G, El-Zoghby Z.M, et al. Survival of patients on the kidney transplant wait list: relationship to cardiac troponin T. Am J Transplant. 2008;8(11):2352-9. doi: 10.1111/j.1600-6143.2008.02395.x
- Havekes B, van Manen J.G, Krediet R.T, et al. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 2006;47(5):823-9. doi: 10.1053/j.ajkd.2006.01.019
- Mc Gill D, Talaulikar G, Potter J.M, Koerbin G, Hickman P.E. Over time, high - sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis - dependent chronic renal failure. Clin Chim Acta. 2010;411(13-14):936-9. doi: 10.1016/j.cca.2010.03.004
- Hassan H.C, Howlin K, Jefferys A, et al. High-Sensitivity Troponin as a Predictor of Cardiac Events and Mortality in the Stable Dialysis Population. Clin Chem. 2014;60(2):389-98. doi: 10.1373/clinchem.2013.207142
- Lentine K.L, Costa S.P, Weir M.R, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012;60(5):434-80. doi: 10.1016/j.jacc.2012.05.008